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RESEARCH
The feasibility of an allergy management 
support system (AMSS) for IgE‑mediated allergy 
in primary care
Bertine M. J. Flokstra‑de Blok1,2* , Thecla M. Brakel1,3, Marian Wubs1, Ben Skidmore1, Janwillem W. H. Kocks1,2, 
Joanne N. G. Oude Elberink2,4, Marie‑Louise A. Schuttelaar5, Jantina L. van der Velde1,2, Thys van der Molen1,2 
and Anthony E. J. Dubois2,6
Abstract 
Background: The allergy management support system (AMSS) was developed to assist general practitioners (GPs) to 
handle the increasing burden of allergic diseases and facilitates the diagnosis and management of allergy. The aim of 
this cluster‑randomized controlled pilot study was to test the feasibility of this AMSS for primary care.
Methods: GPs received diagnostic and management recommendations generated by the AMSS in addition to 
sIgE‑test results (intervention) or GPs received sIgE‑test results only (control). The AMSS recommendations are based 
on the previously developed patient‑completed AMSS questionnaire and sIgE‑test results. The AMSS was considered 
feasible when > 70% of the AMSS recommendations were sent to the GP within ten working days of sIgE‑testing. GPs 
completed a questionnaire on their diagnosis and management before (T1) and after (T2) receiving sIgE test results. 
Agreement and disagreement concerning diagnosis, medication and referrals between GPs and AMSS was investi‑
gated at T1 and T2. A total agreement score between GPs and AMSS was calculated. GPs in the intervention group 
completed a questionnaire to evaluate the utility of the AMSS. Semi‑structured interviews were used to explore the 
motivation of GPs who did not include patients in this pilot study.
Results: Twenty‑seven GPs included 101 patients. Forty‑two patients (72%) completed the AMSS questionnaire in 
the intervention group. The majority of the AMSS recommendations (93%) were returned to the GP within 10 working 
days after sIgE‑test results were known [mean (SD) 4.7 (4.0) working days]. GPs in the intervention group reported 
largely following the AMSS recommendations in 71% of cases. The total agreement scores concerning diagnosis were 
significantly higher (p < 0.001) in the intervention group than the control group [mean (SD); 0.9 (1.8) vs − 0.8 (1.0)]. 
The agreement concerning medication or referral between GPs and AMSS did not differ between the intervention 
and the control group. GPs in the intervention group were reasonably positive about the AMSS. Not enrolling patients 
was not caused by anticipated ineffectiveness of the AMSS.
Conclusion: The AMSS can be considered to be feasible for primary care. GPs tend to follow the AMSS recommenda‑
tions. The AMSS may contribute to the empowerment of GPs to better manage allergy patients in primary care.
Trial registration ISRCTN ISRCTN36780877. Registered 23 November 2017 (retrospectively registered)
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Background
Allergy is one of the most common chronic diseases with 
the number of people suffering from allergic diseases 
increasing worldwide [1–4]. Currently, more than 150 
million people in Europe experience allergic symptoms 
[5]. The number of certified allergists per head of popu-
lation ranges from 1:1,240,000 to 1:16,000 in European 
countries [6]. About 50% of all children under 18  years 
visit their general practitioner (GP) for allergic symptoms 
[7]. Diagnosis and management of patients suspected of 
allergy is often performed by GPs. In many cases, espe-
cially where there are very few allergists operating in 
large populations, GPs are exclusively responsible for 
providing allergy care [8].
GPs report having difficulties in diagnosing and man-
aging allergic patients, including the interpretation 
of specific IgE (sIgE), which they attribute to a lack of 
allergy training [9]. Of the major allergic diseases, food 
allergy has been reported by GPs as the most trouble-
some [10, 11]. In addition, it has been shown that of the 
case mix of patients referred to a regional allergy service 
by GPs, only 43% of patients were diagnosed with an IgE 
mediated allergic disease [12]. In the United Kingdom, it 
has been reported that probably a quarter and maybe half 
of allergy referrals to secondary care may be dealt with 
in primary care by a GP with special interest in allergy 
[13]. These results demonstrate that allergy management 
in primary care is not optimal in most European coun-
tries [14].
Since the specialist-based allergy care model will 
become unsustainable with increasing allergy preva-
lence, a new allergy care model with a more important 
role for the GP is mandatory [8]. Therefore, we devel-
oped an allergy management support system (AMSS) to 
support GPs in diagnosing and managing patients with 
IgE-mediated allergy in primary care [11, 15]. Based on 
a patient-reported history questionnaire and specific IgE 
(sIgE) blood test results, we could demonstrate that the 
AMSS is able to provide a probable diagnosis and recom-
mendations on management of allergic disorders for GPs 
[15]. The primary aim of this pilot study was to test the 
feasibility of an AMSS for primary care. In addition, pre-
liminary effects of the AMSS on diagnosis, medication 
and referrals were investigated. Finally, an evaluation of 
the AMSS by the GPs was carried out.
Methods
Study design
Using a cluster randomized controlled design, GPs in 
the intervention group received AMSS recommenda-
tions in addition to sIgE test results, while GPs in the 
control group performed usual care based on sIgE test 
results only. GPs included patients in the study during 
a 6-month period (from January 2014 until July 2014). 
This pilot study was approved by the local medical ethics 
committee (METc 2013/129) who deemed that the study 
did not fall within the Dutch Medical Research Involv-
ing Human Subjects Act. Participation was voluntary, all 
participants received written information about the study 
and all participants signed an informed consent form.
Participants
All GPs allied to a single regional GP laboratory in the 
northern part of the Netherlands were invited to partici-
pate in this pilot study. The practices of GPs that agreed 
to participate were randomized to the intervention or 
the control group. The GPs included eligible patients 
(both children and adults). The only inclusion criterion 
was that the GP had ordered a sIgE test (usually screen-
ing of inhalant allergens (grass pollen, tree pollen, house 
dust mite, cat, dog, moulds, weed pollen) or food aller-
gens (hen’s egg, milk, cod, wheat, peanut, soy) for that 
particular patient regarding an allergy related problem. 
There were no explicit exclusion criteria. A formal power 
calculation was not applicable, since this is a pilot study 
which aims to investigate the feasibility of the AMSS for 
primary care.
The allergy management support system (AMSS)
Participating patients in the intervention and control 
group completed the AMSS questionnaire and sent 
the questionnaire to the AMSS researchers for analy-
sis together with the sIgE test results. Previously devel-
oped algorithms (for adults and children) were used to 
allocate patients to predefined diagnostic categories and 
consequent recommendations for management [15]. 
In addition, the AMSS questionnaire, sIgE test results 
and resultant AMSS recommendations were checked 
by allergy specialists for inaccuracies or ambiguities. An 
AMSS advice was formulated for patients in the interven-
tion and control group. The AMSS recommendations, 
together with a copy of the completed AMSS question-
naire and the sIgE test outcome, were sent only to the 
GPs in the intervention group by post (Fig. 1). The AMSS 
recommendations formulated for patients in the control 
group were for evaluative purposes only and were not 
made available to the GPs in the control group.
Measures in patients
Participating patients in the intervention and control 
group completed the AMSS questionnaire which consists 
of 12 (mainly) multiple-choice questions on symptoms, 
triggers, severity, medication and symptom control of 
their allergic condition(s) [15].
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Measures in GPs
Efficacy measure and case‑specific evaluation
GPs in both groups completed a short questionnaire with 
multiple-choice questions on diagnosis and management 
(medication, referral and/or non-pharmacotherapeutic 
recommendations). This questionnaire was completed 
on two occasions: at the time of inclusion of the patient 
(T1) and at the time the sIgE test outcomes (and in the 
case of the intervention group, the AMSS recommenda-
tions) were known (T2). In addition, the T2 question-
naire included a question on the GPs’ satisfaction with 
their own management of the patient (5-point scale rang-
ing from very unsatisfied to very satisfied). For GPs in de 
intervention group the T2 questionnaire also included 
three multiple-choice questions to evaluate the case-spe-
cific AMSS recommendations.
Process evaluation
At the end of the inclusion period, the GPs in the inter-
vention group completed a questionnaire to evaluate 
the usefulness of all the AMSS recommendations they 
received during the study and to evaluate the utility of 
the AMSS for primary care. This questionnaire consisted 
of 13 multiple-choice questions and one question to rate 
the AMSS system with a score between 1 (worst) and 10 
(best).
Qualitative evaluation
After the inclusion period, it turned out that 27 (36%) 
of the 75 GPs included patients in the study. Qualita-
tive research was undertaken to eliminate possible (self )
selection bias and ascertain the generalizability of the 
results. Semi-structured interviews were used to explore 
the motivation of GPs who did not include patients in 
the pilot study. In order to obtain diversity in the qualita-
tive sample, GPs were purposively selected based on the 
allocation of the GP to the intervention or control group, 
sex of the GP and location of the GP’s practice. GPs were 
interviewed until saturation was reached. Interviews 
were transcribed verbatim and analyzed using Atlas.ti 
based on the grounded theory [16, 17].
Statistical analysis
The AMSS was considered feasible if > 70% of the AMSS 
recommendations was sent to the GP within 10 working 
days of sIgE testing. Descriptive statistics included mean 
(SD) and percentages. Non-parametric statistics were 
performed using Mann–Whitney U test or Fisher exact 
test. Agreement and disagreement concerning diagnosis, 
medication and referrals between GPs and AMSS were 
investigated at T1 and T2. For each patient, agreement 
was the number of diagnoses made by both the AMSS 
and the GP. There were two types of disagreement: the 
first was the number of diagnoses made by the AMSS but 
not by the GP (referred to hereafter as disagreement A) 
and the second was the number of diagnoses made by the 
GP but not by the AMSS (disagreement B). A total agree-
ment score was then calculated as agreement minus both 
disagreement A and B. Finally, the change of the scores 
were calculated as T2 scores minus T1 scores. The same 
methodology was used for (dis)agreement concerning 
medication prescriptions and referrals. The data was ana-
lysed using SPSS22.0 (IBM, Chicago, USA).
Results
In total 481 GPs were invited to participate in this pilot 
study, of which 75 GPs agreed to participate and 27 GPs 
included at least one patient (37% active GPs). Together 
they included 101 patients of which 66 (66.7%) com-
pleted the AMSS questionnaire (Fig. 2). Table 1 describes 
the included GPs and patients. There was no significant 
difference in the number of (preliminary) diagnoses 
reported by the GPs in the intervention versus the con-
trol group.  
Fig. 1 Schematic representation of the allergy management support 
system (AMSS) [15]
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n=15 (42%)^
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n=58#
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Fig. 2 Flow chart of the pilot study. *GP refused to participate because of being busy/no priority (n = 17), did not expect relevant cases (n = 4), 
moving/changes in practice (n = 6), performs sIgE at other laboratory (n = 4), responded too late (n = 2) or other reason (n = 4). ^Percentages 
represent those of the previous step in the chart. #In total 101 patients were included by GPs. However, for one patient it was unclear by which GP 
she was included and thus whether the GP was from the intervention or control group. Also, she did not complete the AMSS questionnaire and was 
therefore excluded from further analysis
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Feasibility
The majority of the AMSS recommendations (93%) 
were sent back to the GP within 10 working days after 
the sIgE test results were known [mean (SD) 4.7 (4.0) 
days].
Case‑specific evaluation of AMSS recommendations
At T2, GPs in the intervention group reported that the 
AMSS recommendations were complete and to-the-
point in 80% of cases, that they largely agreed with the 
AMSS recommendations in 80% of cases and that they 
largely (71% of cases) or partly (20% of cases) followed 
the AMSS recommendations. Specific patterns for not 
(or partly) following the AMSS recommendations could 
not be determined.
GPs’ satisfaction with their own management
At T2, GPs in the intervention group reported being sat-
isfied to very satisfied regarding the diagnosis and man-
agement recommendation for their patient in 88% of 
cases, whereas GPs in the control group reported this in 
72% of cases (n.s.).
Agreement between AMSS and GPs concerning diagnosis
At T2, significantly more agreement (AMSS +/GP +) 
(p = 0.016), less disagreement A (AMSS +/GP −) 
(p = 0.004) and a higher total agreement score (agree-
ment minus both disagreement A and B) (p = 0.003) con-
cerning diagnosis were found for the intervention group 
compared to the control group. Also, for the change of 
scores (T2 minus T1), significantly more agreement 
(p = 0.001), less disagreement A (p < 0.001) and a higher 
total agreement score (p < 0.001) were found for the 
intervention than for the control group. Disagreement B 
did not differ significantly between the groups (Fig. 3a–
d). Table  2 shows the diagnoses reported by the GPs in 
the intervention group and control group at T1 and T2 
and the probable diagnosis by the AMSS. 
Agreement between AMSS and GPs concerning medication
Table  3 shows the medication reported by the GPs in 
the intervention group and control group at T1 and T2 
Table 1 Descriptive characteristics of the GPs and the patient characteristics at T1
a More than one category was possible
b One missing




Sex, n (m/f ) 25/11 28/11
Households in community, n (< 20,000/> 20,000) 23/13 27/12




Sex, n (m/f ) 18/39b 13/29
Age, mean in years (SD) 28.7 (18.6) 28.5 (17.9)
Age, n (child/adult) 20/38 16/26
Diagnosis by GP, n (%)a
 Allergic rhinitis 36 (62) 24 (57)
 Asthma 11 (19) 10 (24)
 Eczema 5 (9) 4 (10)
 Bee/wasp allergy 0 0
 Medication allergy 0 2 (5)
 Latex allergy 0 0
 Food allergy 9 (16) 8 (19)
 No preliminary diagnosis 3 (5) 3 (7)
 Other 12 (21) 6 (14)
Medication prescribed by GP, n (%) 33 (57) 28 (67)
Other management recommendations by GP, n (%) 29 (50) 21 (50)
Referred by GP, n (%) 3 (5) 3 (7)
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and the medication recommendations of the AMSS. No 
significant differences between intervention and control 
group were found regarding agreement and disagreement 
between AMSS and GPs concerning medication, except 
disagreement A (AMSS +/GP −) at T2 (p = 0.026) with 




























































































(d) Total agreement score (diagnosis)
Intervention group
Control group
Fig. 3 Agreement concerning diagnosis by AMSS and diagnosis reported by GPs (T1 and T2). Selection based on complete data sets at T1 and T2 
(intervention group n = 35, control group n = 18). a Agreement (GP +/AMSS +), b disagreement A (AMSS +/GP −), c disagreement B (AMSS −/
GP +), d total agreement score (agreement minus both disagreement A and B)
Table 2 Diagnosesa reported by  the  GPs in  intervention group and  control group at  T1 and  T2 and  the  probable 
diagnosis by the AMSS (more than one diagnosis possible per patient)
a Presented as n (%)
b GPs in the control group did not receive probable diagnoses from the AMSS. The AMSS formulated these probable diagnoses for evaluative purposes only
Intervention group (n = 35) Control group (n = 18)
T1 AMSS T2 T1 AMSSb T2
Allergic rhinitis 20 (57) 33 (94) 22 (63) 10 (56) 17 (94) 7 (39)
Asthma 9 (26) 25 (71) 14 (40) 7 (39) 15 (83) 6 (33)
Eczema 4 (11) 4 (11) 5 (14) 1 (6) 4 (22) 1 (6)
Bee/wasp allergy 0 2 (6) 0 0 0 0
Medication allergy 0 1 (3) 1 (3) 0 1 (6) 0
Latex allergy 0 1 (3) 0 0 0 0
Food allergy 5 (14) 8 (23) 6 (17) 3 (17) 0 2 (11)
Urticaria 1 (3) 1 (3) 1 (3) 0 0 0
No diagnosis 3 (9) 0 1 (3) 0 1 (6) 3 (17)
Other 8 (23) 2 (6) 7 (20) 2 (11) 5 (28) 3 (17)
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Agreement between AMSS and GPs concerning referrals
At T1, GPs in the intervention and control group 
reported 3 (9%) and 1 (6%) referrals, respectively. The 
AMSS advised 9 (26%) and 5 (29%) referrals in the inter-
vention and control groups, respectively. At T2 the GPs 
in the intervention and control group reported 10 (29%) 
and 3 (18%) referrals, respectively (p = 0.504). No sig-
nificant differences between intervention and control 
group were found regarding agreement and disagreement 
between AMSS and GPs concerning referrals (data not 
shown).
Process evaluation
Of the 15 active GPs in the intervention group, 14 
returned the overall evaluation questionnaire. However, 
one questionnaire was returned blank, thus 13 question-
naires were eligible for analysis. The AMSS was rated by 
the GPs with an average score of 6.7 out of 10. The major-
ity found the AMSS recommendations helpful in mak-
ing the diagnosis and determining the management of 
patients (Fig.  4a). A majority also found that the AMSS 
led to (at least a small) improvement in care and quality 
(Fig. 4b) and wished the AMSS to be integrated into the 
GP information system in the future (Fig. 4c).
Qualitative evaluation
Saturation occurred after ten interviews with inactive 
GPs (i.e. randomized GPs who did not include patients). 
GPs mentioned several reasons for not including patients 
into this study: lack of time (n = 6), not appreciating the 
importance of the study (n = 5), and forgetting about 
the study (n = 4). All GPs emphasized the importance of 
reminders in order to stay involved. Younger GPs pre-
ferred an email as reminder and older GPs preferred a 
visit. No GP indicated that the AMSS system was antici-
pated to be ineffective, or unworkable.
Discussion
The results of this pilot study suggest that the AMSS 
is feasible in primary care. In addition, a majority of 
the GPs reported that they completely followed the 
AMSS recommendations. This was confirmed by the 
Table 3 Medicationa reported by  the  GPs in  intervention group and  control group at  T1 and  T2 and  the  medication 
recommendations of the AMSS
GPs did not report considering immunotherapy for any patients. The AMSS advised immunotherapy as a follow‑up option after instituting pharmacotherapy 16 times 
(46%) in the intervention group and 9 times (50%) in the control group. The AMSS advised venom immunotherapy for a single patient
a Presented as n (%)
b GPs in the control group did not receive AMSS recommendations. The AMSS formulated these recommendations for evaluative purposes only
c For two persons the AMSS advised H2 antagonist as urticaria medication
Intervention group (n = 35) Control group (n = 18)
T1 AMSS T2 T1 AMSSb T2
Antihistamines
 Nasal 2 (6) 1 (3) 3 (9) 0 1 (6) 0
 Ocular 2 (6) 0 2 (6) 1 (6) 0 1 (6)
 Oral 10 (29) 20c (57) 15 (43) 4 (22) 7 (39) 4 (22)
Corticosteroids
 Nasal 9 (26) 16 (46) 15 (43) 3 (17) 9 (50) 4 (22)
 Pulmonary 4 (11) 5 (14) 6 (17) 2 (11) 2 (11) 1 (6)
 Oral 0 0 0 1 (6) 0 1 (6)
 Cutaneous class 1 1 (3) 2 (6) 1 (3) 0 2 (11) 0
 Cutaneous class 2 1 (3) 3 (9) 1 (3) 0 3 (17) 0
 Cutaneous class 3 0 0 0 1 (6) 1 (6) 1 (6)
 Cutaneous class 4 0 0 0 0 0 0
B‑sympathicomimetics
 Short‑acting 7 (20) 20 (57) 9 (26) 3 (17) 13 (72) 4 (22)
 Long‑acting 0 0 1 (3) 0 1 (6) 0
Leukotrien antagonists 0 0 0 1 (6) 0 1 (6)
Combination therapy (corticosteroids with 
B‑sympathicomimetics)
0 1 (3) 1 (3) 2 (11) 0 2 (11)
Decongestants 0 0 0 0 0 0
Emollients 1 (3) 7 (20) 1 (3) 1 (6) 5 (28) 1 (6)
Epinephrine auto‑injector 0 8 (23) 2 (6) 0 3 (17) 0
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greater agreement concerning diagnoses between GPs 
and AMSS in the intervention group compared to the 
control group (usual care). The agreement concerning 
medication or referral between GPs and AMSS did not 
differ between the intervention and the control group. 
The active GPs in the intervention group were reasonably 
positive about the AMSS and foresaw the usefulness of 
the AMSS in the future.
To our knowledge this is the first study that investigates 
a comprehensive allergy support tool in real primary care 
practices. In the past, only one partly comparable initia-
tive was undertaken in the allergy field [18]. However, 
that system added simple standardized sentences to sIgE 
test outcomes and was not based on an extensive, struc-
tured clinical history. The various reasons mentioned by 
inactive GPs who did not enrol patients in our current 
pilot study do not suggest that non-participation was due 
to disapproval or anticipated disappointment with the 
AMSS. This is an important finding in the light of com-
puter decision support systems within routine care. At 
least in asthma it has been shown that these support sys-
tems are rarely used and the advice is not followed [19]. 
This is in contrast to our study where we demonstrated 
that the GPs were following the AMSS advice.
Initially, we hypothesized that the AMSS would pre-
vent referrals. However, in this study GPs in the interven-
tion group tend to refer patients to specialist care more 
often than GPs in the control group. It may be that GPs in 
the control group performing usual care underestimated 
the problems and severity of allergic patients, whereas 
the GPs in the intervention group were alerted by AMSS 
recommendations which encouraged them to refer the 
patient on to specialist care. In principal, this may not be 
a bad thing, as for example one would not wish to delay 
the referral of a patient with sIgE mediated anaphylaxis 
[20]. Based on these findings, the emphasis for future 
work may shift from providing GPs with recommenda-
tions allowing them to manage more allergy patients in 
primary care, to identifying in which environment (pri-
mary or specialist care) the care of the allergic patient 
is likely to be optimized. This suggests perhaps that the 
AMSS, after further refinements may also be used as a 
tool to enable care stratification.
A potential strength of the AMSS in the future is the 
possible learning effect for GPs using this system. By 
receiving individualized patient-specific feedback on each 
case, GPs could become more effective in identifying, 
managing and referring allergic patients. This will also be 
expected to have a learning effect on whether sIgE deter-
minations are required or not and how they should be 
interpreted. In this way, the AMSS meets the unmet need 
of GPs having difficulty with interpretation of sIgE test 
results [9, 21]. Moreover, this direct patient-related learn-
ing is likely to improve care for patients with allergies in 
primary care [22, 23]. In addition, the AMSS should be 
computerized in the future and recommendations should 
preferably be accessed via the GP’s information system 
in a digital format [19]. Other future developments may 
include using the AMSS to guide and rationalize sIgE 
testing and prioritizing referral to secondary care based 
on severity as ascertained by the AMSS. These develop-
ments could further improve the efficiency of the AMSS 
and may contribute to the development of an integrated 
care pathway for allergic patients [24, 25].
One of the strengths of this study is that it was per-
formed in real primary care practices using a cluster 
randomized design. Therefore it gives robust informa-
tion on practical issues relating to the use of the AMSS, 
such as performance and feasibility. In addition, it also 
provides preliminary effect measurements. Furthermore, 





























advice on which sIgE
without sIgE
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Fig. 4 a Helpfulness of the AMSS recommendations, b 
improvements brought about by the AMSS, c further developments 
of the AMSS (as indicated by the GPs in the intervention group)
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the randomized pilot study was enriched with a ques-
tionnaire-based evaluation under the active GPs in the 
intervention group and a qualitative evaluation under the 
inactive GPs, together providing a broad insight into the 
potential utility of the AMSS in primary care.
A limitation of this study is that the AMSS question-
naire is not extensively validated. However, in an earlier 
study we showed good agreement (69.2%) between spe-
cialist’s recommendations (gold standard) and recom-
mendations generated by the AMSS [15]. In addition, 
this pilot study showed that the AMSS questionnaire is 
feasible to advise GPs on diagnosis and management of 
allergic patients in primary care and in that sense the 
questionnaire showed face validity. In addition, the gen-
eralizability of the study may be questioned because of 
the relatively low number of included patients. However, 
since this was a pilot study we had neither the intention 
nor the capacity to include large numbers of patients. 
Larger numbers of patients are needed to further vali-
date, refine and computerize the AMSS before rolling it 
out to full scale. Finally, it should be noted that a history 
questionnaire such as used in the AMSS is not intended 
to replace a specialist consultation, but rather to support 
GPs. GPs will remain ultimately responsible and autono-
mous and may always decide to deviate from the recom-
mendations of the AMSS.
Conclusion
In conclusion, the AMSS may be considered feasible for 
primary care. A majority of the GPs reported that they 
followed the AMSS recommendations completely, that 
they were reasonably positive about the utility of the 
AMSS, and that they were optimistic about future devel-
opments of this system. However, further refinements of 
the AMSS are needed (including computerization) before 
rolling out to full scale. Nevertheless, the AMSS has the 
potential to contribute to the empowerment of GPs, ena-
bling them to better manage allergy patients in primary 
care.
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